$219.88
-2.94-1.32%
Últ. Act.: Oct 2, 7:06 PM
$219.10
-3.72-1.67%
Biogen (BIIB) earnings history, EPS estimates, revenue forecasts and company guidance.
Earnings Per Share (Non-GAAP)
Quarterly Revenue (Billions)
Biogen (BIIB) emitió su última guía sobre julio 29, 2026 para fiscal year 2026. La compañía estimó unas ganancias por acción en el rango de $15.85 - $16.85, en comparación con una estimación de consenso de EPS de $13.45.
En comparación con la previsión anterior, Biogen elevado redujo su previsión de BPA desde un rango anterior de $15.25 - $16.25.
Biogen ha emitido 16 actualizaciones de orientación entre el octubre 25, 2022 y el julio 29, 2026. During this period, the company raised its outlook 6 times and lowered it 5 times, providing investors with insight into management's evolving expectations.
| Metric | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Estimate | $2.35 | $2.95 | $1.62 | $3.89 |
| Actual | $3.60 | $3.57 | $1.99 | $4.81 |
| Surprise | +53.2% | +21.0% | +22.8% | +23.6% |
| Revenue | ||||
| Estimate | $2.42B | $2.25B | $2.21B | $2.34B |
| Actual | $2.74B | $2.48B | $2.28B | $2.53B |
| Surprise | +13.0% | +10.2% | +3.29% | +8.22% |
| Metric | Q3 '26E | Q4 '26E | Q1 '27E | Q2 '27E |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Consensus | $2.04 | $3.27 | $3.80 | $4.62 |
| Revenue | ||||
| Consensus | $2.63B | $2.59B | — | — |
| Trimestre Fiscal | Fecha reportada | EPS real | EPS estimado | Sorpresa % |
|---|---|---|---|---|
| Q2 | Jul 29, 2026 | $3.60 | $2.35 | 53.2 % |
| Q1 | Apr 29, 2026 | $3.57 | $2.95 | 21.0 % |
| Q4 | Feb 6, 2026 | $1.99 | $1.62 | 22.8 % |
| Q3 | Oct 30, 2025 | $4.81 | $3.89 | 23.6 % |
| Trimestre Fiscal | Fecha reportada | Ingresos reales | Ingresos estimados | Sorpresa % |
|---|---|---|---|---|
| Q2 | Jul 29, 2026 | $2.74B | $2.42B | 13.0 % |
| Q1 | Apr 29, 2026 | $2.48B | $2.25B | 10.2 % |
| Q4 | Feb 6, 2026 | $2.28B | $2.21B | 3.29 % |
| Q3 | Oct 30, 2025 | $2.53B | $2.34B | 8.22 % |